EU clears first PD‑1 inhibitor plus ADC regimen for resectable muscle‑invasive bladder cancer regardless of cisplatin eligibility; phase 3 showed EFS HR 0.53 and OS HR 0.65.
SAF reached 1.1 Mt (2.8% share), a near sixfold rise from 2024; supplied at 121 airports, 84% produced in the EU, and 18 Member States host production projects.
CRCF Days launched rollout: certification schemes may seek CRCF recognition; Buyers’ Club to aggregate demand; removals and carbon‑farming methodologies near adoption; financing and de‑risking needed
Applicants across 27 countries submitted large/medium/small projects, pilots and cleantech manufacturing for energy‑intensive, carbon management, renewables and storage; results Oct 2026
siRNA blocking APOC3 cut triglycerides 80% vs 17% in trial; lowered acute pancreatitis rates; given subcutaneously every 3 months; common AEs: hyperglycaemia, headache, nausea.
